Pulmonx
Pulmonx's revenue rose 8.0% to $90 million in fiscal 2025. Its operating margin was −59.3%, up from −68.9% a year earlier. Free cash flow was −$33 million. The diluted share count rose 4.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Pulmonx lost money in fiscal 2025: a net loss of $54 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 180 | 141 | 117 | 102 | 70 |
| Debt incl. finance leases | 17 | 17 | 39 | 40 | 37 |
| Net debt (negative means net cash) | −163 | −124 | −78 | −61 | −33 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.1x | 0.1x | 0.3x | 0.5x | 0.7x |
| Interest coverage | −57.1x | −55.0x | −19.2x | −16.4x | −17.0x |
| Current ratio | 11.8x | 9.1x | 6.5x | 5.6x | 5.1x |
| Quick ratio | 10.9x | 8.3x | 5.8x | 4.9x | 4.3x |
Cash flow
Projections
Project Pulmonx's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Pulmonx says to expect
- Full year 2026: revenue
Pulmonx continues to expect revenue for the full year 2026 to be in the range of $90 million to $92 million.
- Full year 2026: gross margin
The Company now expects gross margin for the full year 2026 to be approximately 77%.
- Full year 2026: total operating expenses
Pulmonx now expects total operating expenses for the full year 2026 to fall within the range of $108 million to $109 million, inclusive of approximately $14 million of non-cash stock-based compensation.
- Full year 2026: change in cash and investments
The Company now expects cash, cash equivalents, and marketable securities to decrease by approximately $22 million for the full year 2026 assuming no additional drawdowns under the Company’s credit facility.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Pulmonx shares on the open market, and 5 insiders sold $547,894, $46,409 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Glendon E. French IIIPresident and CEO, Director | Sold | 41,882 | $2.26 | $94,653 | Form 4 |
| Sep 1, 2026 | David Aaron LehmanGeneral Counsel | Sold | 14,334 | $2.26 | $32,395 | Form 4 |
| Sep 1, 2026 | Srikanth RadhakrishnanChief Science & Techn. Officer | Sold | 14,245 | $2.26 | $32,194 | Form 4 |
| Sep 1, 2026 | Geoffrey Beran RoseChief Commercial Officer | Sold | 7,879 | $2.26 | $17,807 | Form 4 |
| Jun 2, 2026 | Glendon E. French IIIPresident and CEO, Director | Sold | 13,511 | $1.57 | $21,212 | Form 4 |
| Jun 1, 2026 | Glendon E. French IIIPresident and CEO, Director | Sold | 42,638 | $1.54 | $65,663 | Form 4 |
| Jun 1, 2026 | David Aaron LehmanGeneral Counsel | Sold | 14,594 | $1.54 | $22,475 | Form 4 |
| Jun 1, 2026 | Srikanth RadhakrishnanChief Science &Techn. Officer | Sold | 14,497 | $1.54 | $22,325 | Form 4 |
| Jun 1, 2026 | Geoffrey Beran RoseChief Commercial Officer | Sold | 8,023 | $1.54 | $12,355 | Form 4 |
| Mar 2, 2026 | Glendon E. French IIIPresident and CEO, Director | Sold | 67,813 | $1.43 | $96,973 | Form 4 |
| Mar 2, 2026 | David Aaron LehmanGeneral Counsel | Sold | 12,237 | $1.43 | $17,499 | Form 4 |
| Mar 2, 2026 | Srikanth RadhakrishnanChief Science &Techn. Officer | Sold | 10,483 | $1.43 | $14,991 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 9 | 3 of 9 | 3 of 9 |
| Rule of 40 | −28.0% | −17.4% | −28.3% |
| Altman Z'' | −3.10 | −6.07 | −11.04 |
| Accruals ratio | −12.5% | −14.6% | −14.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 2 of 9 | 3 of 9 | 3 of 9 |
Compare
Put Pulmonx side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Pulmonx | FY25 | 8.0% | −59.3% | −36.3% | −183.3% | — | 3 | |
| Ceribell | FY25 | 36.1% | −65.6% | −46.7% | — | — | — | Compare |
| Kestra Medical Technologies | FY26 | 59.0% | −141.6% | −122.6% | — | — | 4 | Compare |
| Delcath Systems | FY25 | 129.1% | 0.8% | 24.6% | 2.8% | −101.4x | 6 | Compare |
| Butterfly Network | FY25 | 19.0% | −88.5% | −16.4% | — | — | — | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 20 | 33 | 33 | 48 | 54 | 69 | 84 | 90 |
| Revenue growth | — | 62.9% | 0.4% | 47.9% | 10.8% | 28.0% | 22.0% | 8.0% |
| Gross profit | 12 | 22 | 21 | 36 | 40 | 51 | 62 | 67 |
| Research and development | 7 | 6 | 8 | 13 | 15 | 18 | 18 | 20 |
| Operating income | −15 | −18 | −32 | −47 | −59 | −62 | −58 | −54 |
| Net income | −18 | −21 | −32 | −49 | −59 | −61 | −56 | −54 |
| Diluted EPS (US$) | −11.03 | −11.66 | −3.16 | −1.35 | −1.59 | −1.60 | −1.44 | −1.33 |
| Diluted shares (millions) | 2 | 2 | 10 | 36 | 37 | 38 | 39 | 41 |
| Cash flow | ||||||||
| Cash from operations | −18 | −21 | −31 | −41 | −45 | −38 | −32 | −32 |
| Capital expenditure | 0 | 1 | 1 | 4 | 1 | 1 | 1 | 0 |
| Free cash flow | −19 | −21 | −32 | −45 | −46 | −38 | −33 | −33 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 3 | 10 | 16 | 22 | 23 | 21 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 4 | 28 | 232 | 180 | 141 | 117 | 102 | 70 |
| Debt incl. finance leases | — | — | 17 | 17 | 17 | 39 | 40 | 37 |
| Total assets | — | 54 | 264 | 235 | 194 | 178 | 163 | 129 |
| Total liabilities | — | 36 | 38 | 42 | 40 | 60 | 77 | 75 |
| Shareholders' equity | −167 | −187 | 226 | 193 | 154 | 118 | 86 | 54 |
| Margins and ratios | ||||||||
| Gross margin | 61.4% | 68.8% | 64.8% | 73.6% | 74.3% | 73.9% | 74.0% | 74.2% |
| Operating margin | −75.2% | −54.7% | −98.8% | −97.7% | −109.3% | −90.2% | −68.9% | −59.3% |
| Net margin | −92.4% | −63.5% | −98.5% | −100.5% | −109.8% | −88.6% | −67.3% | −59.7% |
| Free cash flow margin | −93.5% | −65.9% | −96.4% | −93.1% | −86.5% | −55.9% | −39.4% | −36.3% |
| Rule of 40 (growth + FCF margin) | — | −3.0% | −95.9% | −45.1% | −75.6% | −28.0% | −17.4% | −28.3% |
| Return on capital | — | — | — | — | −152.1% | −138.0% | −139.6% | −183.3% |
| Return on equity | — | — | −166.3% | −23.2% | −33.9% | −44.7% | −55.2% | −77.2% |
| Return on assets | — | — | −20.3% | −19.5% | −27.5% | −32.8% | −33.1% | −37.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |